Company: STAA
Filing Date: 2025-08-05
Form Type: DEFA14A
Source: 0001193125-25-173111
Chunk: 0

Company: STAAR SURGICAL CO
Filing Date: 2025-08-05
Form: DEFA14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 
 14a-6(e)(2))                                                       |

| ☐ | Definitive Proxy Statement |

| ☐ | Definitive Additional Materials |

| ☒ | Soliciting Material under §240.14a-12 |

STAAR SURGICAL COMPANY (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box):

| ☒ | No fee required. |

| ☐ | Fee paid previously with preliminary materials. |

| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 
 14a-6(i)(1) and 0-11                                                           |

The following email and employee Q&A were sent to employees of STAAR Surgical Company (the “Company”) on August 4, 2025: To: All Employees of STAAR From: Steve Farrell, CEO, STAAR Subject: An Exciting New Chapter for STAAR: Joining Forces with Alcon Dear Team, Today marks a significant milestone in the journey of STAAR. As of Monday, August 4, the company has entered into a definitive agreement for Alcon to acquire STAAR Surgical. This transaction is anticipated to close in six to twelve months, subject to customary closing conditions and approvals. STAAR’s Board of Directors and leadership team carefully evaluated this opportunity. We believe that joining forces with Alcon will create increased opportunities for EVO ICLs & lens-based refractive surgery. This acquisition will allow us to accelerate EVO ICL adoption by leveraging Alcon’s global commercial expertise and footprint. We’re confident this transaction serves the best interest of patients, customers, employees and shareholders. More specifically, joining Alcon enables us to:

| • |     | Expand our reach and capabilities: Leveraging Alcon’s resources and marketing expertise will enable us 
 to combine our joint experience and resources around refractive surgical solutions.                    |

| • |     | Accelerate innovation: Enhanced resources across the two